Summary & Overview
HCPCS C9098: Ciltacabtagene Autoleucel, BCMA-Directed CAR T Therapy
HCPCS Level II code C9098 designates a single therapeutic dose of ciltacabtagene autoleucel, an autologous BCMA-directed CAR T-cell therapy that includes leukapheresis and dose preparation. This code captures the product and preparatory procedures for a high-cost, specialized cellular therapy used in hematologic malignancies, and its accurate coding affects billing, clinical workflows, and patient access across the country.
Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, coding and billing benchmarks, and clinical context for use of this CAR T-cell therapy. The publication summarizes typical sites of service, common billing modifiers provided in the input, and the operational considerations tied to a per-dose product code.
The report provides succinct benchmarks and policy context relevant to hospital and specialty infusion settings, including reimbursement drivers, prior authorization considerations, and the role of product-level HCPCS coding in care coordination. Data not available in the input is noted where applicable; the narrative focuses on national implications for coding, billing, and clinical administration of this advanced cellular therapy.
Billing Code Overview
HCPCS Level II code C9098 represents ciltacabtagene autoleucel, up to 100 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, billed per therapeutic dose. The description includes procedures for leukapheresis and dose preparation as part of the single therapeutic product delivery.
Service Type: Cellular gene therapy product with associated leukapheresis and dose preparation procedures
Typical Site of Service: Hospital inpatient or hospital outpatient setting, specialized infusion centers, and accredited cellular therapy facilities
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory multiple myeloma who has exhausted standard therapies and is eligible for BCMA-directed CAR-T cell therapy. The care pathway begins with referral from the treating hematologist/oncologist for evaluation of organ function, performance status, and prior treatment history. Pre-treatment assessments include detailed history and physical exam, baseline labs (CBC, CMP, coagulation studies), infectious disease screening (CMV, hepatitis B/C, HIV), and imaging as indicated. Leukapheresis is performed to collect autologous T cells, followed by cryopreservation and shipment to the manufacturer for C9098 manufacturing. Bridging therapy may be administered while cells are processed. Prior to infusion, patients receive lymphodepleting chemotherapy (commonly fludarabine and cyclophosphamide) in an inpatient or monitored outpatient setting. The therapeutic dose of C9098 (ciltacabtagene autoleucel, up to 100 million autologous BCMA-directed CAR-positive T cells) is prepared per manufacturer specifications and administered under close monitoring for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Post-infusion monitoring includes inpatient observation for acute toxicities, serial labs, neurologic assessments, and access to critical care if needed. Follow-up involves scheduled outpatient visits for assessment of response, management of delayed toxicities, and long-term surveillance for secondary malignancies and persistent cytopenias.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|